Compare Bitdeer Technologies Group (BTDR) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bitdeer Technologies Group vs State Street SPDR S&P Biotech ETF — how do they compare? Bitdeer Technologies Group trades at $12.81 (market cap $3.01B), while State Street SPDR S&P Biotech ETF trades at $153.56. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Bitdeer Technologies Group nearer its low. Which is the better fit depends on your goals.
| BTDR | XBI | |
|---|---|---|
Market Cap | $3.01B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $25.90 | $164.28 |
52-Week Low | $7.28 | $85.16 |
Enterprise Value | $4.77B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BTDR trades at $12.13, down 8.73% over 24 hours, with technical indicators signaling a bearish trend. The stock shows strong analyst support with 9 out of 11 ratings as Buy and a consensus price target of $23.40, but fundamentals reveal challenges: negative net income margin of -26.96% and three consecutive quarterly earnings misses. Recent news highlights expansion into AI infrastructure, including a new $36 million manufacturing facility in Nevada and an AI cloud platform award in June 2026.
The outlook is mixed: bullish analyst sentiment and strategic growth in AI and mining infrastructure offer upside potential, but persistent losses, negative cash flow from operations, and high debt-to-asset ratio of 35.69% pose significant risks. Investors should weigh the company's expansion against its financial health and sector volatility.
XBI trades at $155.34, down 2.32% on the day, but maintains a bullish technical outlook with strong momentum indicators. The biotech ETF has gained significant attention after a 17% monthly surge, driven by sector rotation and M&A activity. Analyst coverage remains limited with a single hold rating, though recent news highlights biotech's strong performance amid market volatility.
The ETF offers exposure to biotech's resurgence with AI drug discovery and deal momentum as catalysts. However, high volatility and concentrated sector risk require careful position sizing. Current technical strength suggests potential for continued upside if sector momentum persists.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bitdeer Technologies Group
Bitdeer is a world-leading technology company for blockchain and high-performance computing. It provides comprehensive digital asset mining solutions, including cloud mining, hosting, and data center management.
Read more on BTDR →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
